Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score

EuroIntervention 2017;12:2110-2117 published online ahead of print March 2017. DOI: 10.4244/EIJ-D-16-00974

Luis Ortega-Paz
Luis Ortega-Paz1, MD; Davide Capodanno2, MD, PhD; Tommaso Gori3, MD, PhD; Holger Nef4, MD; Azeem Latib5, MD; Giuseppe Caramanno6, MD; Carlo Di Mario7,11, MD; Christoph Naber8, MD; Maciej Lesiak9, MD; Piera Capranzano2, MD; Jens Wiebe4, MD; Julinda Mehilli10, MD; Aleksander Araszkiewicz9, MD; Stelios Pyxaras8, MD; Alessio Mattesini11, MD; Salvatore Geraci6, MD; Toru Naganuma5, MD; Antonio Colombo5, MD; Thomas Münzel3, MD; Manel
1. Cardiovascular Institute, Department of Cardiology, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain; 2. Ferrarotto Hospital, University of Catania, Catania, Italy; 3. Medizi

Aims: The aim of the study was to develop a scoring model to evaluate the quality of bioresorbable vascular scaffold (BVS) implantation and determine the model’s usefulness in predicting

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

bioresorbable scaffoldsclinical trialrisk stratification
Coronary interventionsStents and scaffoldsTools, devices and techniques
Read next article
First-in-man six-month results of a surface-modified coronary stent system in native coronary stenosis

Latest news